New drug trial aims to protect kidneys from further damage
NCT ID NCT07419828
Summary
This large Phase 3 study is testing whether an investigational drug called HRS-1780 can slow the decline of kidney function in adults with chronic kidney disease. Nearly 2,000 participants will receive either HRS-1780 tablets or a placebo in addition to their standard care. The main goal is to see if the drug can better preserve kidney function over 32 months compared to a dummy pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Conditions
Explore the condition pages connected to this study.